|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
Are the right patients receiving the right drugs in the right dosage at the right time? Preventing medication errors is high on the agenda not only of hospitals, but the pharmaceutical wholesalers, the pharmaceutical industry and also governments worldwide. The American health care sector is focusing on minimising errors in administering medication. By scanning medication at the patient's bedside, errors can be reduced by as much as 50 per cent or more according to the Federal Drug Administration (FDA). It is no wonder therefore that in mid-2003, the FDA ruled that there should be bar codes on each unit dose. Much research is carried out in order to calculate the percentage of medication errors occurring. Just about every country worldwide has done at least one research project on this subject.
Depending on which research report you read (and depending on the definition of medication error used) the percentage of medication errors varies between 10 and 25 per cent. Almost 0.5 per cent result in permanent injury and 0.25 per cent of patients die due to the wrong medicine or wrong dosage being administered. Although it looks like a small percentage in relation to the size of the population, this number is unacceptable. In addition, the costs of recovery, such as the expense of contra-medication and an extra stay in hospital, are estimated to be an annual ˆ300 million in countries such as The Netherlands. These figures are worrying, especially if you have ever been a patient, and solutions must be found.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
